Building a Better RSV Vaccine
Experimental Vaccine Shows Early Promise in a Clinical Trial
A novel experimental vaccine against respiratory syncytial virus (RSV), a leading cause of severe respiratory illness in the very young and the old, has shown early promise in a phase 1 clinical trial. Researchers from the Vaccine Research Center in the National Institute of Allergy and Infectious Diseases developed a vaccine candidate called DS-Cav1. One dose prompted large increases in RSV-neutralizing antibodies that were sustained for several months.
Read more at https://irp.nih.gov/catalyst/v27i5/research-briefs.
This page was last updated on Thursday, March 31, 2022